[
  {
    "ts": null,
    "headline": "Here's Why Amgen (AMGN) Gained But Lagged the Market Today",
    "summary": "The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=2ba54ad17eeb15ee76f9d1db1b40e0943a7d978a46ce71b25b12f084369eca87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734994218,
      "headline": "Here's Why Amgen (AMGN) Gained But Lagged the Market Today",
      "id": 132132719,
      "image": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=2ba54ad17eeb15ee76f9d1db1b40e0943a7d978a46ce71b25b12f084369eca87"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock rises Monday, still underperforms market",
    "summary": "Amgen Inc. stock rises Monday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=70ccdcc714a881d3edf67d3de3ce157b8fd95618bac906b1e426b3fd94458533",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734971940,
      "headline": "Amgen Inc. stock rises Monday, still underperforms market",
      "id": 132147762,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock rises Monday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=70ccdcc714a881d3edf67d3de3ce157b8fd95618bac906b1e426b3fd94458533"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
    "summary": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
    "url": "https://finnhub.io/api/news?id=43d97b071a263f9bb49a3c83572213b633af95cb84fdba908a8325f163d7f5d4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734968760,
      "headline": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
      "id": 132145561,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
      "url": "https://finnhub.io/api/news?id=43d97b071a263f9bb49a3c83572213b633af95cb84fdba908a8325f163d7f5d4"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=818702966625ee5e4ffff5088e320d6fea335ceb250eb045bf184d7bc8ca4b08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734962411,
      "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
      "id": 132121437,
      "image": "https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=818702966625ee5e4ffff5088e320d6fea335ceb250eb045bf184d7bc8ca4b08"
    }
  },
  {
    "ts": null,
    "headline": "Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?",
    "summary": "Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
    "url": "https://finnhub.io/api/news?id=9451830a5429e23ec275207e5ae78d2edd9d5184d0f23ff9c9e99be5f8e507b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734961680,
      "headline": "Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?",
      "id": 132121438,
      "image": "https://media.zenfs.com/en/zacks.com/c044de49a07dc50d6afbd14846fc644c",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
      "url": "https://finnhub.io/api/news?id=9451830a5429e23ec275207e5ae78d2edd9d5184d0f23ff9c9e99be5f8e507b1"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
    "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
    "url": "https://finnhub.io/api/news?id=31cd3e22b1483200418a001b32ab70a52840e9a671ba2882befbfdaa994d9946",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734959760,
      "headline": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
      "id": 132121202,
      "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
      "url": "https://finnhub.io/api/news?id=31cd3e22b1483200418a001b32ab70a52840e9a671ba2882befbfdaa994d9946"
    }
  },
  {
    "ts": null,
    "headline": "Hot Obesity Drug Market Will Keep Investors Gripped Next Year",
    "summary": "(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNovo sh",
    "url": "https://finnhub.io/api/news?id=8627274ffe00c98c4f130143de0907fd1d833a955e597066c397b45dfb1c4edc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734956524,
      "headline": "Hot Obesity Drug Market Will Keep Investors Gripped Next Year",
      "id": 132117993,
      "image": "https://media.zenfs.com/en/bloomberg_markets_842/d6d8e08ee049366cd32f1c0ad2b087b7",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNovo sh",
      "url": "https://finnhub.io/api/news?id=8627274ffe00c98c4f130143de0907fd1d833a955e597066c397b45dfb1c4edc"
    }
  },
  {
    "ts": null,
    "headline": "2 Excellent Dividend Stocks to Buy on the Dip",
    "summary": "AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common.  Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.  The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that transaction, emraclidine, failed a pair of phase 2 studies.",
    "url": "https://finnhub.io/api/news?id=dd89758c20e726a1dcb8a744f07157cad74c75fb20707e21f3733b108b54b176",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734946320,
      "headline": "2 Excellent Dividend Stocks to Buy on the Dip",
      "id": 132117199,
      "image": "https://g.foolcdn.com/editorial/images/801657/pharmacist-talking-to-patient.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common.  Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.  The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that transaction, emraclidine, failed a pair of phase 2 studies.",
      "url": "https://finnhub.io/api/news?id=dd89758c20e726a1dcb8a744f07157cad74c75fb20707e21f3733b108b54b176"
    }
  }
]